Boston Scientific to acquire Augmenix for $500M

Boston Scientific Corp. (NYSE:BSX) will acquire Augmenix Inc. (Waltham, Mass.) for $500 million in cash up front and up to $100 million in sales milestones. Boston Scientific will gain Augmenix's SpaceOAR hydrogel, which is used to reduce high dose radiation to the rectum in prostate cancer patients receiving radiation therapy. The product has CE Mark and FDA approval...